NURS617 EXAM 1 Actual Exam 2026/2027 Complete
Questions and Verified Answers with Detailed
Rationales Pharmacotherapeutics Review Grade A
100% Correct Pass Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS
Q1: A 68-year-old patient with atrial fibrillation is started on warfarin. The NP understands that
warfarin's anticoagulant effect is monitored using which laboratory value, and what is the
therapeutic range for most indications?
A. aPTT; 1.5-2.5 times control
B. INR; 2.0-3.0. [CORRECT]
C. Anti-Xa; 0.5-1.0 IU/mL
D. Bleeding time; 3-9 minutes
Correct Answer: B
Rationale: Warfarin's anticoagulant effect is monitored using the International Normalized Ratio
(INR). For most indications, including atrial fibrillation and venous thromboembolism, the
therapeutic target INR is 2.0-3.0 (B). aPTT (A) is used to monitor unfractionated heparin. Anti-
Xa (C) is used to monitor LMWH. Bleeding time (D) is not used to monitor warfarin.
Q2: A patient taking carbamazepine for epilepsy is prescribed a new medication metabolized by
CYP3A4. The NP anticipates which pharmacokinetic interaction?
A. Decreased metabolism of the new drug due to enzyme inhibition
B. Increased metabolism of the new drug due to enzyme induction. [CORRECT]
C. Decreased absorption of the new drug due to chelation
D. Increased renal excretion of the new drug
Correct Answer: B
Rationale: Carbamazepine is a potent CYP450 enzyme inducer (specifically CYP3A4) that
increases the metabolism of drugs metabolized by this enzyme system (B). This occurs because
enzyme inducers increase the synthesis of metabolic enzymes, leading to decreased drug
concentrations and potentially therapeutic failure. Enzyme inhibition (A) would be caused by
drugs like ketoconazole or grapefruit juice.
,Q3: A patient with liver cirrhosis is prescribed a drug with high first-pass metabolism. The NP
expects which alteration in drug disposition?
A. Decreased bioavailability due to increased hepatic extraction
B. Increased bioavailability due to decreased hepatic extraction. [CORRECT]
C. Decreased volume of distribution due to increased protein binding
D. Increased renal clearance due to compensatory mechanisms
Correct Answer: B
Rationale: First-pass metabolism occurs when a drug is extensively metabolized by the liver
before reaching systemic circulation. In liver cirrhosis, decreased hepatic blood flow and
hepatocellular dysfunction reduce first-pass extraction, resulting in increased bioavailability (B)
and potentially toxic drug concentrations. This necessitates dose reduction for high first-pass
drugs like propranolol or morphine.
Q4: A patient is prescribed a drug that is a prodrug requiring CYP2D6 metabolism for activation.
The patient is a poor CYP2D6 metabolizer. The NP anticipates which clinical consequence?
A. Increased therapeutic effect due to prolonged drug half-life
B. Therapeutic failure due to inadequate formation of active metabolite. [CORRECT]
C. Increased adverse effects due to accumulation of active drug
D. No change in clinical effect due to compensatory pathways
Correct Answer: B
Rationale: Prodrugs require metabolic conversion to active compounds. CYP2D6 poor
metabolizers have deficient enzyme activity, resulting in inadequate conversion of prodrugs
(such as codeine to morphine or tamoxifen to endoxifen) to their active forms, leading to
therapeutic failure (B). This pharmacogenomic consideration is critical for personalized
prescribing.
Q5: A patient taking a highly protein-bound drug (99% bound to albumin) develops
hypoalbuminemia due to malnutrition. The NP monitors for which potential effect?
A. Decreased drug effect due to increased protein binding
B. Increased free drug concentration and potential toxicity. [CORRECT]
C. Decreased drug metabolism due to reduced hepatic blood flow
D. Increased renal excretion of the bound drug
Correct Answer: B
, Rationale: Only unbound (free) drug is pharmacologically active. When albumin levels decrease,
less drug is bound to protein, increasing the free fraction (B). For highly protein-bound drugs
like warfarin or phenytoin, this can lead to increased pharmacological effect and toxicity despite
normal total drug concentrations, requiring careful monitoring and potential dose reduction.
Q6: A patient receives two drugs that both prolong the QT interval. The NP recognizes this as
which type of drug interaction?
A. Pharmacokinetic interaction involving enzyme inhibition
B. Pharmacodynamic additive effect. [CORRECT]
C. Pharmacokinetic interaction involving protein binding displacement
D. Pharmacodynamic antagonistic effect
Correct Answer: B
Rationale: When two drugs produce the same pharmacological effect through the same
mechanism (QT prolongation via potassium channel blockade), their combined effect is additive
(B), significantly increasing the risk of torsades de pointes. This is a pharmacodynamic
interaction, not a pharmacokinetic interaction involving metabolism or distribution.
Q7: A patient with renal impairment is prescribed a drug primarily eliminated by glomerular
filtration. The NP calculates the dosing regimen based on which pharmacokinetic parameter?
A. Volume of distribution
B. Clearance. [CORRECT]
C. Bioavailability
D. Therapeutic index
Correct Answer: B
Rationale: Clearance (Cl) is the pharmacokinetic parameter that determines the rate of drug
elimination and is used to calculate maintenance doses. For drugs eliminated renally, creatinine
clearance or estimated glomerular filtration rate (eGFR) guides dose adjustment (B). Decreased
renal clearance necessitates dose reduction or extended dosing intervals to prevent accumulation
and toxicity.
Q8: A patient taking phenytoin presents with toxic symptoms despite a total serum concentration
within the therapeutic range. The patient has low albumin. The NP interprets this as:
A. Inadequate dosing requiring increased phenytoin dose
B. Increased free fraction due to decreased protein binding causing toxicity. [CORRECT]
Questions and Verified Answers with Detailed
Rationales Pharmacotherapeutics Review Grade A
100% Correct Pass Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS
Q1: A 68-year-old patient with atrial fibrillation is started on warfarin. The NP understands that
warfarin's anticoagulant effect is monitored using which laboratory value, and what is the
therapeutic range for most indications?
A. aPTT; 1.5-2.5 times control
B. INR; 2.0-3.0. [CORRECT]
C. Anti-Xa; 0.5-1.0 IU/mL
D. Bleeding time; 3-9 minutes
Correct Answer: B
Rationale: Warfarin's anticoagulant effect is monitored using the International Normalized Ratio
(INR). For most indications, including atrial fibrillation and venous thromboembolism, the
therapeutic target INR is 2.0-3.0 (B). aPTT (A) is used to monitor unfractionated heparin. Anti-
Xa (C) is used to monitor LMWH. Bleeding time (D) is not used to monitor warfarin.
Q2: A patient taking carbamazepine for epilepsy is prescribed a new medication metabolized by
CYP3A4. The NP anticipates which pharmacokinetic interaction?
A. Decreased metabolism of the new drug due to enzyme inhibition
B. Increased metabolism of the new drug due to enzyme induction. [CORRECT]
C. Decreased absorption of the new drug due to chelation
D. Increased renal excretion of the new drug
Correct Answer: B
Rationale: Carbamazepine is a potent CYP450 enzyme inducer (specifically CYP3A4) that
increases the metabolism of drugs metabolized by this enzyme system (B). This occurs because
enzyme inducers increase the synthesis of metabolic enzymes, leading to decreased drug
concentrations and potentially therapeutic failure. Enzyme inhibition (A) would be caused by
drugs like ketoconazole or grapefruit juice.
,Q3: A patient with liver cirrhosis is prescribed a drug with high first-pass metabolism. The NP
expects which alteration in drug disposition?
A. Decreased bioavailability due to increased hepatic extraction
B. Increased bioavailability due to decreased hepatic extraction. [CORRECT]
C. Decreased volume of distribution due to increased protein binding
D. Increased renal clearance due to compensatory mechanisms
Correct Answer: B
Rationale: First-pass metabolism occurs when a drug is extensively metabolized by the liver
before reaching systemic circulation. In liver cirrhosis, decreased hepatic blood flow and
hepatocellular dysfunction reduce first-pass extraction, resulting in increased bioavailability (B)
and potentially toxic drug concentrations. This necessitates dose reduction for high first-pass
drugs like propranolol or morphine.
Q4: A patient is prescribed a drug that is a prodrug requiring CYP2D6 metabolism for activation.
The patient is a poor CYP2D6 metabolizer. The NP anticipates which clinical consequence?
A. Increased therapeutic effect due to prolonged drug half-life
B. Therapeutic failure due to inadequate formation of active metabolite. [CORRECT]
C. Increased adverse effects due to accumulation of active drug
D. No change in clinical effect due to compensatory pathways
Correct Answer: B
Rationale: Prodrugs require metabolic conversion to active compounds. CYP2D6 poor
metabolizers have deficient enzyme activity, resulting in inadequate conversion of prodrugs
(such as codeine to morphine or tamoxifen to endoxifen) to their active forms, leading to
therapeutic failure (B). This pharmacogenomic consideration is critical for personalized
prescribing.
Q5: A patient taking a highly protein-bound drug (99% bound to albumin) develops
hypoalbuminemia due to malnutrition. The NP monitors for which potential effect?
A. Decreased drug effect due to increased protein binding
B. Increased free drug concentration and potential toxicity. [CORRECT]
C. Decreased drug metabolism due to reduced hepatic blood flow
D. Increased renal excretion of the bound drug
Correct Answer: B
, Rationale: Only unbound (free) drug is pharmacologically active. When albumin levels decrease,
less drug is bound to protein, increasing the free fraction (B). For highly protein-bound drugs
like warfarin or phenytoin, this can lead to increased pharmacological effect and toxicity despite
normal total drug concentrations, requiring careful monitoring and potential dose reduction.
Q6: A patient receives two drugs that both prolong the QT interval. The NP recognizes this as
which type of drug interaction?
A. Pharmacokinetic interaction involving enzyme inhibition
B. Pharmacodynamic additive effect. [CORRECT]
C. Pharmacokinetic interaction involving protein binding displacement
D. Pharmacodynamic antagonistic effect
Correct Answer: B
Rationale: When two drugs produce the same pharmacological effect through the same
mechanism (QT prolongation via potassium channel blockade), their combined effect is additive
(B), significantly increasing the risk of torsades de pointes. This is a pharmacodynamic
interaction, not a pharmacokinetic interaction involving metabolism or distribution.
Q7: A patient with renal impairment is prescribed a drug primarily eliminated by glomerular
filtration. The NP calculates the dosing regimen based on which pharmacokinetic parameter?
A. Volume of distribution
B. Clearance. [CORRECT]
C. Bioavailability
D. Therapeutic index
Correct Answer: B
Rationale: Clearance (Cl) is the pharmacokinetic parameter that determines the rate of drug
elimination and is used to calculate maintenance doses. For drugs eliminated renally, creatinine
clearance or estimated glomerular filtration rate (eGFR) guides dose adjustment (B). Decreased
renal clearance necessitates dose reduction or extended dosing intervals to prevent accumulation
and toxicity.
Q8: A patient taking phenytoin presents with toxic symptoms despite a total serum concentration
within the therapeutic range. The patient has low albumin. The NP interprets this as:
A. Inadequate dosing requiring increased phenytoin dose
B. Increased free fraction due to decreased protein binding causing toxicity. [CORRECT]
